Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability

Journal of Physiological Sciences

Volumn 57, Issue 1, 2007, Pages 43-49

  Seki, Ritsuko ^a   Okamura, Takashi ^a   Ide, Tatsuya ^a   Kage, Masayoshi ^a   Sata, Michio ^a   Uyesaka, Nobuhiro ^b   Maruyama, Toru ^c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis; Eicosapentaenoic acid (EPA); Erythrocytes; Filterability; Oxidative stress

Indexed keywords

ALPHA INTERFERON; ICOSAPENTAENOIC ACID; RIBAVIRIN; ANTIOXIDANT; ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ERYTHROCYTE FILTERABILITY; ERYTHROCYTE MEMBRANE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FUNCTION; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; OXIDATION; STATISTICAL SIGNIFICANCE; BLOOD; BLOOD RHEOLOGY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; ERYTHROCYTE; ERYTHROCYTE DEFORMABILITY; HOSPITALIZATION; JAPAN; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTIOXIDANTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HEMORHEOLOGY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; JAPAN; MIDDLE AGED; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248198540     PISSN: 18806546     EISSN: None     Source Type: Journal    
DOI: 10.2170/physiolsci.RP010506     Document Type: Article

References (30)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-47.
2. McHutchison JG. Hepatitis C advances antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol. 2002;17:431-41.
3. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990;12:1139-46.
4. Ahmed A, Keeffe EB. Treatment strategies for chronic hepatitis C: update since 1997 National Institutes of Health Consensus Development Conference. J Gastroenterol Hepatol. 1999;14 (Suppl S):12-8.
5. Van Vlierberghe H, Delanghe JR, De Vos M, Lerox-Roel, The members of the BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001;34:911-6.
6. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara G, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997-1004.
7. Ohnishi Y, Fujino T, Satoh A, Takeda S, Harada M, Uyesaka N, Maruyama, T. Effects of oligomeric procyanidins (OPCs) on human erythrocyte filterability and microcirculation. J Jpn Soc Biorheol. 2005;19:83-92.
8. Nilsson GE, Tenland T, Oberg PA. Evaluation of laser-Doppler flowmeter for measurement of tissue blood flow. IEEE Trans Biomed Eng. 1980;10:597-604.
9. Arai K, Iino M, Shio H, Uyesaka N. Further investigations of red cell deformability with nickel mesh. Biorheology. 1990;27:47-65.
10. Nakamura T, Hasegawa S, Shio H, Uyesaka N. Rheologic and pathophysiologic significance of red cell passage through narrow pores. Blood Cells. 1994;20:151-65.
11. Seki R, Okamura T, Maruyama T, Tanaka K, Ide T, Kage M, Sata M, Uyesaka N. Quantitative studies on the impaired filterability of erythrocytes from patient with liver cirrhosis. J Jpn Soc Biorheol. 2005;19:50-9.
12. Koyama T, Maruyama T, Seki R, O'Rear EA, Shio H, Uyesaka N. A new quantitative filtration apparatus to evaluate erythrocyte deformability. Jpn J Physiol. 2003;53:481-6.
13. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993;328:73-80.
14. 2+ influx and cAMP-mediated signaling pathways. Am J Physiol. 1997;273:C1828-34.
15. Ide T, Okamura T, Kumashiro R, Koga Y, Hino T, Hisamochi A, Ogata K, Tanaka K, Kuwahara R, Seki R, Sata M. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. Int J Mol Med. 2003;11:729-32.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology. 1994;19:1513-20.
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15-20.
18. Owen JS, Bruckdorfer KR, Day RC, McIntyre N. Decreased erythrocyte membrane fluidity and altered lipid composition in human liver disease. J Lipid Res. 1999;23:124-32.
19. Dieterich DT, Spivak JL. Hematologic disorder associated with hepatitis C virus infection and their management. Clin Infect Dis. 2003;37:533-41.
20. Carrell RW, Winterbourn CC, Rachmilewitz EA. Activated oxygen and haemolysis. Br J Haematol. 1975;30:259-64.
21. Jarolim P, Lahav M, Liu SC, Palek J. Effects of hemoglobin oxidation products on the stability of red cell membrane skeletons and the associations of the skeletal proteins: correlation with a release of hemin. Blood. 1990;70:2125-31.
22. Uyesaka N, Hasegawa S, Ishioka N, Ishioka R, Shio H, Schechter AN. Effects of superoxide anions on red cell deformability and membrane proteins. Biorheology. 1992;29:217-29.
23. Okamoto K, Maruyama T, Kaji Y, Harada M, Mawatari S, Fujino T, Uyesaka N. Verapamil prevents impairment in filterability of human erythrocytes exposed to oxidative stress. Jpn J Physiol. 2004;54:39-46.
24. Ota Y, Sasagawa T, Suzuki K, Tomioka K, Nagai A, Niiyama G, Kawanaka M, Yamada G, Okita M. Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition. 2004;20:358-63.
25. Carbonell T, Rodenas, J, Miret S, Mitjavila MT. Fish oil and oxidative stress by inflammatory leukocytes. Free Radic Res. 1997;27:591-7.
26. De Caterina R, Zampolli A. n-3 fatty acids: antiatherosclerotic effects. Lipids. 2001;36:S69-78.
27. Frenoux J-M R, Prost ED, Belleville JL, Prost JL. A poly fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr. 2001;131:39-45.
28. Mori TA, Woodman RJ, Burke V, Puddey IB, Groft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35:772-81.
29. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndrome. Ren Fail. 1991;13:87-93.
30. Kontrinis N, Agarwal K, Dieterich D. Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord. 2004;4:S39-47.